Anzeige
Mehr »
Login
Samstag, 13.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
X-Leak: Jetzt der Mega-Meilenstein - Kurseskalation vorprogrammiert?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QAME | ISIN: US92556V1061 | Ticker-Symbol: VIA
Tradegate
12.04.24
21:54 Uhr
10,610 Euro
-0,030
-0,28 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
S&P 500
1-Jahres-Chart
VIATRIS INC Chart 1 Jahr
5-Tage-Chart
VIATRIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,59010,63012.04.
10,60010,73012.04.

Aktuelle News zur VIATRIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.04.Viatris- Theramex deal for women's care products raises antitrust concerns in U.K.24
04.04.UK watchdog says Theramex-Viatris deal raises competition concerns10
02.04.Teva, Viatris revive patent challenge on J&J's long-acting schizophrenia blockbuster Invega Sustenna27
01.04.Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent35
01.04.Teva, Viatris win new chance to challenge J&J schizophrenia drug patent28
01.04.Ocuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner Viatris349CANONSBURG (dpa-AFX) - Monday, Ocuphire Pharma, Inc. (OCUP) announced the commercial launch of Ryzumvi, a 0.75% phentolamine ophthalmic solution in the United States by its partner Viatris Inc....
► Artikel lesen
01.04.Viatris Announces US Commercial Launch Of RYZUMVl 0.75%207CANONSBURG (dpa-AFX) - Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced...
► Artikel lesen
01.04.Ocuphire Pharma: Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris280FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment...
► Artikel lesen
27.03.Kursgewinne für die Viatris-Aktie (10,9234 €)299Der Anteilsschein von Viatris notiert heute etwas fester. Zuletzt zahlten Investoren für das Wertpapier 11,82 US-Dollar. Für das Wertpapier von Viatris steht gegenwärtig ein Wertanstieg 1,90 Prozent...
► Artikel lesen
26.03.Viatris' Indore Site Receives International Sustainability Rating System Certification252NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Viatris' Indore manufacturing site has received certification for International Sustainability Rating System (ISRS), 9th Edition - Process Safety, from...
► Artikel lesen
18.03.Viatris: Driven to Success: Former Taxi Operator Builds Sales Career Through Listening, Learning373NORTHAMPTON, MA / ACCESSWIRE / March 18, 2024 / Viatris Growing up in Zimbabwe, Happiness Ngwenya couldn't have foreseen how his conventional path through school and higher education would lead to...
► Artikel lesen
18.03.Idorsia und Viatris schliessen Transaktion ab - Idorsia erhält Vorabzahlung84
18.03.Idorsia Pharmaceuticals Ltd: Idorsia and Viatris successfully close the transaction for the global research and development collaboration337Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 18, 2024Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ:...
► Artikel lesen
15.03.Viatris executive sells over $3 million in company stock31
15.03.Looking Into Viatris' Recent Short Interest11
14.03.Is Viatris a Great Dividend Stock or Just a Value Trap?61
12.03.Viatris: Inclusion, Belonging, and the Making of a Role Model800NORTHAMPTON, MA / ACCESSWIRE / March 12, 2024 / ViatrisBy: Niki KapsambelisWhen Lauren Kashtan thinks about the point in her life when she started to realize what she stood for, she zeroes in on middle...
► Artikel lesen
11.03.FDA rejects Mapi-Viatris long-acting version of Teva's Copaxone53
11.03.US STOCKS Viatris, National Fuel Gas, Moderna14
11.03.Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi8
Seite:  Weiter >>
164 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,2,9